Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Consensus PT from Analysts

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $10.10.

A number of brokerages recently weighed in on CRDF. Wall Street Zen upgraded shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Noble Financial started coverage on shares of Cardiff Oncology in a research note on Monday, January 5th. They set an “outperform” rating and a $12.00 target price on the stock. Piper Sandler dropped their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st.

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. acquired a new position in shares of Cardiff Oncology during the 4th quarter valued at $3,388,000. Laurion Capital Management LP lifted its holdings in shares of Cardiff Oncology by 37.2% in the third quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after buying an additional 668,590 shares during the period. Acorn Capital Advisors LLC boosted its stake in Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after buying an additional 553,317 shares in the last quarter. Flputnam Investment Management Co. boosted its stake in Cardiff Oncology by 1,008.8% during the third quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock valued at $1,230,000 after buying an additional 543,370 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Cardiff Oncology by 441.5% during the fourth quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock worth $546,000 after acquiring an additional 158,519 shares during the period. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Price Performance

Shares of CRDF stock opened at $1.55 on Friday. Cardiff Oncology has a 12-month low of $1.48 and a 12-month high of $4.56. The firm has a market capitalization of $105.96 million, a price-to-earnings ratio of -2.25 and a beta of 1.32. The business has a 50 day simple moving average of $1.89 and a 200 day simple moving average of $2.20.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.07. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%.The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. On average, equities analysts anticipate that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.